Research projects

Alligator’s early-stage research projects include several projects within immuno-oncology, based on Alligator’s bispecific format RUBY™, with components created using ALLIGATOR-GOLD® and FIND®. Alligator is actively seeking collaboration partners on this programs.

For further information, please contact Peter Ellmark, Chief Scientific Officer.

Peter Ellmark
CSO
  • Independent in relation to the Company and its management: Yes
  • Independent in relation to major shareholders: Yes
  • Holdings in Alligator: 40,000 shares and 250,000 warrants in program TO 2022/2025 I.
  • Other current positions: None
Updated 2022-07-18